POS0639 LONG-TERM EFFECTIVENESS OF THE RITUXIMAB HALF DOSE REGIMEN FOLLOWING A RESPONSE TO THE LICENSED DOSE IN RHEUMATOID ARTHRITIS

Background:Following initial treatment with rituximab (RTX) full dose (2x1000mg), B-cell numbers are often lower than baseline. The half dose regime (2x500mg) has been reported to be similarly effective [1]; however, there is limited long-term data on the effectiveness of switching to RTX half-dose from the real-world perspective.Objectives:To compare the 3-year RTX regime retention between patients receiving retreatment with half-dose and full-dose of RTX, and assess factors associated with maintenance of 2x500mg, with a view to establish an optimal long-term retreatment strategy in RA.Methods:An observational study was conducted on 755 consecutive RTX-treated RA patients in a single centre for over 20 years. Of these, 165/755 (22%) received at least one cycle of 2x500mg. Long-term effectiveness was assessed using RTX retention rate. Drug survival of patients treated with 2x500mg was compared with 200 RA patients receiving 2x1000mg throughout the study, matched to the number of cycle when the 2x500mg regime was initiated.Results:Of the 165 patients who received 2x500mg, 81.8% were female; mean age was 63.4 (26-91) years; mean disease duration 15.5 (2-53) years; 57 (34.5%) were bDMARDs-naïve; 121 (74%) were on concomitant DMARDs and mean DAS-28 was 3.9 (SD 1.29) at the half dose initiation. At 3 years, the retention rate was 38% for patients recieving 2x500mg compared to 87% for those on 2x1000mg; HR for half dose discontinuation was 6.17 [95%CI (3.91-12.27); p<0.001] (Figure 1A).The main reasons for 2x500mg discontinuation were poor EULAR response (30%); moderate EULAR response (30%); shorter duration of response compared to the full dose (22%); and incomplete B-cell depletion (17%). The majority of these patients (87.9%) were switched back to 2x1000mg, 5.1% received other bDMARDs and 7.1% did not receive further DMARDs.In multivariable analysis, previous TNFi use was associated with 3-year maintenance of the 2x500mg dose [OR 2.63 (1.12-6.10); p=0.024]; while higher plasmablasts at 2x500mg initiation was associated with shorter maintenance of this regime [OR 0.78 (0.67-0.97); p=0.028].There were no significant differences in 5-year RTX retention rates between patients receiving 2x500mg and switched back to 2x1000mg vs those receiving 2x1000mg throughout the study (Log-Rank=0.186) (Figure 1B).Conclusion:The use of RTX half-dose regimen was associated with poor retention at 3 years. Nevertheless, where loss of effectiveness occurs post-2x500mg initiation, switching back to 2x1000mg appears to be a pragmatic option. Patients with previous TNFi exposure and lower plasmablasts may be most suited to be commenced on the 2x500mg dose for long-term disease control.References:[1]Mariette X, et al. ARD 2014Acknowledgements:Leeds CaresDisclosure of Interests:Leticia Garcia-Montoya: None declared, Md Yuzaiful Md Yusof: None declared, Gisela Eugénio: None declared, Jean Baptiste Candelier: None declared, Sudipto Das Speakers bureau: Dr Das has received honoraria from Roche, Edward Vital Speakers bureau: Dr Vital has received honoraria from Roche, Consultant of: Dr Vital has received honoraria a from Roche, Grant/research support from: Dr Vital has received research grant support from Roche, Paul Emery Speakers bureau: Professor Emery has received honoraria from Roche, Consultant of: Professor Emery has received consultant fees from Roche, Grant/research support from: Professor Emery has received research grants paid to his employer from Roche.

Download Full-text

Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT+C) in esophageal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.4_suppl.118 ◽

2016 ◽

Vol 34 (4_suppl) ◽

pp. 118-118 ◽

Cited By ~ 1

Author(s):

Somnath Mukherjee ◽

Chris Hurt ◽

Stephen Falk ◽

Simon Gollins ◽

John Staffurth ◽

...

Keyword(s):

Esophageal Cancer ◽

Phase Ii ◽

Randomised Trial ◽

Multivariable Analysis ◽

Dose Intensity ◽

Long Term Results ◽

Full Dose ◽

Number Of Patients ◽

Patterns Of Recurrence

118 Background: One of the largest trials in dCRT for localised oesophageal cancer, SCOPE 1 tested the role of adding cetuximab to conventional dCRT, and showed that this was associated with greater toxicity and worse survival. Here we present the long-term outcomes. Methods: Phase II/III trial. Randomisation: cisplatin 60mg/m2 D1 and capecitabine 625mg/m2 daily D1-21 for 4 cycles with/without Cetuximab 400mg/m2 D1 followed by 250mg/m2weekly. RT: 50Gy in 25 fractions given concurrent with cycles 3 and 4. Recruitment: Feb 2008 - Feb 2012, when the IDMC recommended trial closure on the basis of futility. Results: 258 patients (dCRT = 129; dCRT+C = 129) were recruited from 36 centres. Median follow-up (IQR): 46.7 (36.0-49.0) months for all surviving pts. 65.1% (dCRT arm) and 69.8% (dCRT+C arm) of patients had died. Esophageal cancer was the cause in 82.1% and 86.7% of deaths respectively (p = 0.41). Median OS months (95% CI) was 34.5 (24.7-42.3) in dCRT and 24.7 (18.6-31.3) in dCRT+C (HR 1.25, p = 0.137); corresponding 3-year OS (95% CI) was 47.2% (38.2%-55.7%) and 37.6% (29.1%-46.0%). Median PFS (95% CI): 24.1 (15.3-29.9) and 15.9 (10.7-20.8) months respectively (HR1.28, p = 0.114). There was some evidence that local PFS (within RT field) was lower in the dCRT+C arm (HR1.38, p = 0.051). On multivariable analysis including treatment arm, Stage I-II ds (vs Stage III), full-dose RT and higher cisplatin dose intensity ( ≥ 75% vs < 75%) were associated with improved OS and PFS. Patterns of recurrence (n [%]) were similar in both arms (see table). In dCRT arm, 31/38 pts (81.6%) with local relapse within the RT field compared to 40/48 (83.3%) in the dCRT+C arm (p = 0.8). Conclusions: The mature analysis shows unprecedented survival in dCRT arm, comparable to surgical trials (e.g. 3-year OS % [95% CIs] in OE05: CF 39 [35, 44] and ECX 42 [37, 46], in OE02: 31 [27, 36]). OS inferiority of dCRT+C is no longer statistically significant. The lower PFS (within RT field) in the dCRT+C arm was consistent with the lower number of patients receiving full dose of RT in the dCRT+C arm. Clinical trial information: 47718479. [Table: see text]

Download Full-text

Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy

Annals of Hematology ◽

10.1007/s00277-020-04208-x ◽

2020 ◽

Vol 99 (10) ◽

pp. 2357-2366

Author(s):

Henna-Riikka Junlén ◽

Sandra Lockmer ◽

Eva Kimby ◽

Björn Engelbrekt Wahlin

Keyword(s):

T Cell ◽

Follicular Lymphoma ◽

B Cell ◽

Univariate Analysis ◽

Multivariable Analysis ◽

Cell Subset ◽

Response Duration ◽

Cell Counts ◽

Pre Treatment

Abstract Rituximab monotherapy is widely used for follicular lymphoma. However, there are no established predictors for response or response duration. We analyzed the long-term prognostic relevance of pre-treatment absolute blood counts of lymphocytes with subsets and monocytes in 265 follicular lymphoma patients, uniformly treated with rituximab without chemotherapy, in two Nordic Lymphoma Group trials. There were 265 previously untreated, stage II–IV follicular lymphoma patients with a median follow-up of over 10 years. Absolute B cell counts ≥ median (0.09 × 109/L) were an independent predictor for shorter time to next treatment or death (multivariable analysis P = 0.010). In univariate analysis, absolute monocyte counts ≥ median (0.5 × 109/L) did not correlate with time to next treatment or death, but with inferior overall survival (P = 0.034). Absolute T cell or T cell subset counts were not predictive for outcome. High absolute B cell counts, possibly reflecting circulating lymphoma cells, have an unfavorable impact on time to next treatment or death in patients treated with rituximab without chemotherapy.

Download Full-text

Evaluation of three tagging methods in the sea urchin Diadema antillarum

Journal of the Marine Biological Association of the United Kingdom ◽

10.1017/s0025315415000302 ◽

2015 ◽

Vol 95 (6) ◽

pp. 1255-1260

Author(s):

Ruber Rodríguez-Barreras ◽

Alberto M. Sabat

Keyword(s):

Sea Urchin ◽

Field Experiments ◽

Retention Rate ◽

Pairwise Comparison ◽

The Other ◽

Retention Rates ◽

Diadema Antillarum ◽

Pit Tags ◽

Long Term Studies

Multiple tagging devices have been developed for long-term studies and estimating demographic parameters in sea urchins. In this study, we evaluated the use of passive integrated transponders (PIT-tag), and two types of nylon tags (T-bar and S-tag) in the sea urchin Diadema antillarum by measuring retention rate and apparent survival. The PIT-tags exhibited the highest retention, followed by T-bars, and lastly the S-tags. Differences in recapture were detected among the three types of tags (H = 6.99, P = 0.030). An a posteriori pairwise comparison test found significant differences between PIT-tags and each of the other two types (P < 0.05), whereas T-bar and S-tag did not exhibit significant differences between them (P > 0.05). The semi-captivity experiment exhibited similar results to the field experiment in terms of retention. This experiment also found higher mortality with T-bars. Differences between previous studies conducted under controlled conditions and experiments carried out in the field reflect high variability and the necessity of testing tagging procedures under both settings. The S-tag induced high spine autotomy and low retention; whereas the T-bar demonstrated low retention and low survival. Although the retention rate of PIT-tags was significantly higher than the other two, retention rates were still too low for practical utility in long-term field experiments. In conclusion, the present study does not support the use of any of these tags for long-term studies in D. antillarum.

Download Full-text

P207 A proposal for individually tailored rituximab treatment based on clinical and B-cell biomarkers for remission maintenance in ANCA associated vasculitis

Rheumatology ◽

10.1093/rheumatology/keab247.202 ◽

2021 ◽

Vol 60 (Supplement_1) ◽

Author(s):

Jack E Arnold ◽

Edward M J Vital ◽

Shouvik Dass ◽

Aamir Aslam ◽

Andy C Rawstron ◽

...

Keyword(s):

B Cells ◽

Complete Remission ◽

B Cell ◽

Multivariable Analysis ◽

Research Support ◽

P Values ◽

Final Model ◽

Time To Relapse ◽

Cell Repopulation ◽

Relapse Rates

Abstract Background/Aims Time-to-relapse after rituximab for ANCA vasculitis is variable and optimal retreatment strategy is unclear. We previously showed that repopulation of naïve B-cells at 6 months predicts sustained response. Our objective was to evaluate clinical and B-cell predictors for relapse in multivariable analysis to develop a retreatment algorithm. Methods An observational study was conducted in 60 rituximab-treated AAV patients over 10-years. Complete response was defined as a Birmingham Vasculitis Activity Score (BVAS) v3.0=0. Repeat rituximab cycles were given on clinical relapse. Naïve, memory B-cells and plasmablasts were measured using highly sensitive flow cytometry. Clinical and B cell predictors were analysed in multivariable analysis (MVA) to develop a retreatment algorithm. Results Patients were: 33/60 (55%) male, mean(SD) age 51(19), 39/60 (65%) received concomitant immunosuppressants and 54/60 (90%) had prior therapy with cyclophosphamide. Median times to retreatment for cycles 1-5 were 87, 71, 65, 59 and 86 weeks. Over 417 patient-years follow up, 137 relapses occurred in 50 patients; 16 (in 14 patients) were major (renal=7, neurological=4, ENT=3 and lungs=2). The major-relapse rate was 3.8/100 patient-years. Results of MVA are shown in the table. With naïve B-cell repopulation at 6 months, relapse rates at 12 and 18 months were 5% and 16%, versus 45% and 59% without naïve repopulation (p < 0.001). Relapse rates at 18 and 24 months were 17% and 54% with naïve repopulation at 12 months versus and 29% and 71% without (p = 0.045). AUROC for time-to-relapse was greater if retreatment was guided by naïve B-cell repopulation than if ANCA and/or CD19+ return was used at 6 months, 0.82 and 0.52 respectively. Conclusion These results suggest the following: (i) all patients should receive an oral immunosuppressant; (ii) patients with incomplete remission should be retreated at 6 months; (iii) patients with complete remission but absent naïve B cells at 6 months should be retreated at 6 months; (iv) patients with complete remission and naïve B-cell return may not be appropriate for fixed retreatment. For this last group monitoring of clinical symptoms and B-cells may be effective and future work will address this further. This algorithm could avoid hypogammaglobulinaemia due to unnecessary retreatment. P207 Table 1:Factors associated with time-to-relapse to first cycle rituximabRisk FactorsUnivariable analysisHR (95% CI); p-values(with multiple imputation)Multivariable analysis (MVA)HR (95% CI); p-values(with multiple imputation)Age, per 10 years (BL)1.01 (0.86 – 1.17); p = 0.954Not included in MVAFemale (BL)1.15 (0.65 – 2.02); p = 0.629Not included in MVADisease duration, years (BL)1.06 (0.98 – 1.15); p = 0.160Included in MVA but removed from final model as p < 0.20Concomitant immunosuppressant (BL)0.69 (0.39 – 1.22); p = 0.2050.48 (0.24 – 0.94); p = 0.034Positive ANCA immunofluorescence (BL)0.89 (0.46 – 1.71); p = 0.725Not included in MVAPositive anti-PR3/anti-MPO (BL)0.57 (0.31 – 1.06); p = 0.077Included in MVA but removed from final model as p < 0.20CRP, mg/L (BL)1.00 (0.99 – 1.01); p = 0.456Not included in MVABVAS 3.0 per point score (BL)0.99 (0.94 – 1.05); p = 0.763Included in MVA but removed from final model as p < 0.20VDI per point score (BL)1.14 (0.87 – 1.50); p = 0.353Not included in MVANaïve B-cells, x 10 9/L* (BL)1.00 (1.00 – 1.01); p = 0.797Not included in MVAMemory B-cells, x 10 9/L* (BL)1.01 (1.00 – 1.02); p = 0.0401.01 (1.00 – 1.02); p = 0.045Plasmablasts, x 10 9/L* (BL)1.04 (0.94 – 1.16); p = 0.459Not included in MVAComplete depletion at 6 Weeks post-RTX0.90 (0.50 – 1.61); p = 0.721Not included in MVAComplete Response (26Wk)0.34 (0.19 – 0.61); p < 0.0010.24 (0.12 – 0.50); p < 0.001Positive ANCA immunofluorescence (26Wk)0.99 (0.56 – 1.75); p = 0.962Not included in MVAPositive anti-PR3/anti-MPO (26Wk)0.79 (0.44 – 1.42); p = 0.426Not included in MVACRP, mg/L (26Wk)0.99 (0.97 – 1.02); p = 0.618Not included in MVANaïve B-cell repopulation (26Wk)0.38 (0.19 – 0.76); p = 0.0060.43 (0.22 – 0.84); p = 0.013Memory B-cell repopulation (26Wk)0.45 (0.20 – 0.99); p = 0.046Included in MVA but removed from final model as p < 0.20Plasmablast cell repopulation (26Wk)1.14 (0.61 – 2.13); p = 0.675Not included in MVABL = baseline, 26Wk = 26 weeks. Disclosure J.E. Arnold: None. E.M.J. Vital: Honoraria; Roche, GSK, AstraZeneca. S. Dass: Honoraria; Roche, GSK. A. Aslam: None. A.C. Rawstron: None. S. Savic: Honoraria; Novartis, Swedish Orphan Biovitrum, Sire. Grants/research support; Novartis, Swedish Orphan Biovitrum, Octapharma, CSL Behring. P. Emery: Consultancies; BMS, Abbott, Pfizer, MSD, Novartis, Roche, UCB. Grants/research support; Abbott, BMS, Pfizer, MSD, Roche. M. Md Yusof: None.

Download Full-text

OP0057 A PERSONALISED RITUXIMAB RETREATMENT APPROACH BASED ON CLINICAL AND B-CELL BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2021-eular.2193 ◽

2021 ◽

Vol 80 (Suppl 1) ◽

pp. 30.1-30

Author(s):

J. Arnold ◽

E. Vital ◽

S. Dass ◽

A. Aslam ◽

A. Rawstron ◽

...

Keyword(s):

B Cells ◽

B Cell ◽

Cox Regression ◽

Multivariable Analysis ◽

Complete Response ◽

Clinical Relapse ◽

Research Support ◽

Anca Associated Vasculitis ◽

Time To Relapse ◽

Cell Repopulation

Background:Time-to-relapse after rituximab for ANCA-associated vasculitis (AAV) is variable and optimal retreatment strategy has been unclear. We previously showed that repopulation of naïve B-cells at 6 months predicts sustained response [1].Objectives:In AAV following rituximab induction, to evaluate clinical and B-cell predictors of relapse in order to develop a retreatment algorithm.Methods:An observational study was conducted in 60 rituximab-treated AAV patients followed for over 10 years. Complete response (CR) was defined as Birmingham Vasculitis Activity Score v3.0 = 0. Retreatment was given on clinical relapse, defined as new features or worsening of persistent disease (not by biomarker status). Peripheral B-cell subsets were measured using highly sensitive flow cytometry. Predictors were tested using multivariable Cox-Regression.Results:Median times-to-retreatment for rituximab cycles 1-5 were 87, 71, 65, 59 and 86 weeks. Over 417 patient-years follow-up, 137 relapses occurred in 50 patients; 16 (in 14 patients) were major (renal=7, neurological=4, ENT=3 and respiratory=2). The major-relapse rate was 3.8/100 patient-years. In multivariable analysis, concomitant immunosuppressant [HR 0.48 (95% CI 0.24–0.94)], achieving CR [0.24 (0.12–0.50)] and naïve B-cell repopulation at 6 months [0.43 (0.22–0.84)] were associated with longer time-to-relapse. Higher baseline memory B-cells [1.01 (1.00–1.02)] were associated with a shorter time-to-relapse. AUROC for prediction of time-to-relapse was greater if guided by naïve B-cell repopulation than if ANCA and/or CD19+ return at 6 months had been used, 0.82 and 0.52 respectively.Conclusion:These data suggest that all patients should receive concomitant oral immunosuppressant. Those with incomplete response or with absent naïve B-cells should be retreated at 6 months. Patients with complete response and naïve repopulation at 6 months should not receive fixed retreatment. This algorithm could reduce hypogammaglobulinaemia due to unnecessary retreatment.Figure 1.A personalised retreatment algorithm for rituximab in ANCA-associated vasculitisReferences:[1]Md Yusof et al. Annals of rheumatic diseases (2015) PMID: 25854586.Disclosure of Interests:Jack Arnold: None declared, Edward Vital Speakers bureau: Roche, GSK and AstraZeneca, Consultant of: Roche, GSK and AstraZeneca, Grant/research support from: Roche, GSK and AstraZeneca, Shouvik Dass Speakers bureau: Roche and GSK, Aamir Aslam: None declared, Andrew Rawstron: None declared, Sinisa Savic: None declared, Paul Emery Speakers bureau: BMS, Abbott, Pfizer, MSD, Novartis, Roche and UCB, Consultant of: BMS, Abbott, Pfizer, MSD, Novartis, Roche and UCB, Grant/research support from: Abbott, BMS, Pfizer, MSD and Roche., Md Yuzaiful Md Yusof: None declared

Download Full-text

Facility-Level Factors Associated With CNA Turnover and Retention: Lessons for the Long-Term Services Industry

The Gerontologist ◽

10.1093/geront/gnaa098 ◽

2020 ◽

Vol 60 (8) ◽

pp. 1436-1444 ◽

Cited By ~ 1

Author(s):

Katherine A Kennedy ◽

Robert Applebaum ◽

John R Bowblis

Keyword(s):

Retention Rate ◽

Retention Rates ◽

Nursing Assistant ◽

Turnover Rates ◽

High Turnover ◽

Term Care ◽

Factors Associated ◽

The Mean ◽

Facility Level

Abstract Background and Objectives Certified nursing assistant (CNA) turnover and retention are critical aspects of facilities’ ability to provide cost-effective, high-quality person-centered care. Previous studies and industry practice often treat turnover and retention as similar concepts, assuming that low turnover and high retention are synonymous. The study addressed the question of whether turnover and retention rates differ and if so, what those differences mean for nursing home practice, policy, and research. Research Design and Methods This study examines facility-level factors associated with CNA retention and turnover rates using 2015 data from the Ohio Biennial Survey of Long-Term Care Facilities, Ohio Medicaid Cost Reports, Certification and Survey Provider Enhanced Report, and the Area Health Resource File. Using bivariate tests and regression analysis, we compare rates and the factors associated with retention and turnover. Results The mean facility annual retention rate was 64% and the mean annual turnover rate was 55%. As expected, there was a statistically significant and negative correlation between the rates (r = −0.26). However, some facilities had both high retention and high turnover and some had low rates for both measures. Not all the variables that are associated with turnover are also associated with retention. Discussion and Implications CNA retention is not simply the absence of CNA turnover. Given the differences, nursing homes may need to use strategies and policies designed to target a particular stability measure.

Download Full-text

AB0229 A NATIONAL, MULTICENTER, SECONDARY DATA USE STUDY EVALUATING EFFICACY AND RETENTION OF FIRST-LINE BIOLOGIC TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN REAL-LIFE SETTING FROM TURKBIO REGISTRY

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2021-eular.2928 ◽

2021 ◽

Vol 80 (Suppl 1) ◽

pp. 1140-1141

Author(s):

A. Yazici ◽

Ö. Özdemir Işik ◽

E. Dalkiliç ◽

S. S. Koca ◽

Y. Pehlivan ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Real World ◽

Retention Rate ◽

Real Life ◽

Retention Rates ◽

First Line ◽

Research Support ◽

Biologic Treatment ◽

Number Of Patients

Background:Tocilizumab (TCZ) is a human anti-interleukin (IL)-6 receptor antibody approved in Turkey for the treatment of rheumatoid arthritis (RA).Objectives:In this study our purpose was to describe the disease activity, quality of life (QoL), and retention rate in RA patients who were prescribed TCZ as first-line biologic treatment in a real-world setting.Methods:Anonymized patient registry of TURKBIO was used based in a national, multicenter, and retrospective context. We conducted a search in the registry between years 2013 and 2020 and included adult RA patients who were prescribed with TCZ as their first-line biologic treatment with a post-TCZ follow-up of at least 6 months. CDAI, DAS28-(ESR), and HAQ-DI scores in 6, 12, and 24 months were obtained. Pairwise comparison was carried out for survey scores across baseline and timepoints. Subgroup analysis for route of TCZ administration was performed. EULAR response criteria were used for response evaluation. Retention of TCZ was evaluated by Kaplan-Meier analysis.Results:Overall,130 patients with a mean RA duration of14 years were included in the study. 87.7% of the patients were female and mean age was53 (SD; 15.0). Median duration of follow-up was 18.5 months. Majority (90.8%) of patients were given tocilizumab via intravenous route at baseline. Number of patients with ongoing TCZ treatment and follow-up at 6, 12, and 24 months were 121 (93%), 85 (65%), and 46 (35%), respectively. Remission rates at 6, 12, and 24 months per CDAI (<2.8) and DAS28-(ESR) (<2.6) scores were 61.5%, 44.6%, 30%, and 54.6%, 40.8%, 27.7%, respectively. CDAI, DAS28-(ESR) and HAQ-DI survey scores significantly improved at 6, 12 and 26 months, respectively (p<0.001) (Table 1) in both IV and SC TCZ subgroups. At 6, 12 and 24months 74.8%, 82.5% and 86.4% of patients achieved a EULAR good response respectively. Twenty-three patients (17.6%) discontinued TCZ at 24 months. Of these, 19 patients discontinued due to unsatisfactory response. Retention rates of TCZ at 6, 12, and 24 months were 93%, 84.3%, and 72.2%, respectively (Figure 1).Conclusion:TCZ as a first-line biologic treatment was found to be clinically effective in this real-world study with a high retention rate. These results are in line with the results gathered from previous TCZ controlled and real-life studies in which TCZ was found clinically safe and effective.References:[1]Haraoui B, Casado G, Czirjak L, Taylor A, Dong L, Button P, Luder Y, Caporali R. Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies. Rheumatol Ther. 2019 Jun;6(2):231-243.[2]Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R. The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. Autoimmun Rev. 2017 Dec;16(12):1185-1195.[3]Haraoui B, Jamal S, Ahluwalia V, Fung D, Manchanda T, Khraishi M. Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results from an Observational, Noninterventional Study. Rheumatol Ther. 2018 Dec; 5(2): 551–565.Disclosure of Interests:Ayten Yazici Speakers bureau: PFIZER, AbbVie, NOVARTIS, Özlem Özdemir Işik: None declared, Ediz Dalkiliç Speakers bureau: AbbVie, UCB Pharma, PFIZER, Roche, MSD, NOVARTIS, Süleyman Serdar Koca Speakers bureau: MSD, NOVARTIS, GILEAD, PFIZER, ABDI IBRAHIM, UCB Pharma, AMGEN, SANOFİ, Yavuz Pehlivan Speakers bureau: PFIZER, NOVARTIS, MSD, CELLTRION, Consultant of: PFIZER, Soner Şenel: None declared, Nevsun Inanc Speakers bureau: NOVARTIS, PFIZER, ABDI IBRAHIM, JANNSEN, Paid instructor for: NOVARTIS, PFIZER, ABDI IBRAHIM, JANNSEN, Consultant of: NOVARTIS, PFIZER, ABDI IBRAHIM, JANNSEN, Grant/research support from: NOVARTIS, PFIZER, ABDI IBRAHIM, JANNSEN, Servet Akar Speakers bureau: LILLY, MSD, NOVARTIS, GILEAD, PFIZER, ABDI IBRAHIM, JANNSEN, UCB Pharma, AMGEN, Paid instructor for: LILLY, NOVARTIS, GILEAD, PFIZER, ABDI IBRAHIM, UCB, AMGEN, Grant/research support from: PFIZER, Sema Yilmaz: None declared, Özgül Soysal Gündüz: None declared, Ayse Cefle Speakers bureau: UCB Pharma, PFIZER, MSD, AbbVie, AMGEN, NOVARTIS, Fatos Onen Speakers bureau: AbbVie, LILLY, MSD, NOVARTIS, GILEAD, PFIZER, ABDI IBRAHIM, JANNSEN, UCB Pharma, AMGEN, İbrahim Etem-MENARINI, Paid instructor for: AbbVie, LILLY, NOVARTIS, GILEAD, PFIZER, ABDI IBRAHIM, UCB Pharma, AMGEN, İbrahim Etem-MENARINI, Grant/research support from: PFIZER

Download Full-text

Effectiveness of Structured Physical Activity (PA) Interventions through the evaluation of PA levels, Adoption, Retention, Maintenance and Adherence Rates – A Systematic Review

10.31236/osf.io/a5fc2 ◽

2019 ◽

Cited By ~ 1

Author(s):

Nadja Willinger ◽

James Steele ◽

Lou Atkinson ◽

Gary Liguori ◽

Alfonso Jimenez ◽

...

Keyword(s):

Physical Activity ◽

Systematic Review ◽

Retention Rate ◽

Retention Rates ◽

Group Differences ◽

Intervention Implementation ◽

Short Term ◽

Database Screening ◽

Structured Interventions

Background: Structured physical activity (PA) interventions can potentially be implemented in a variety of facilities, and therefore can reach a large proportion of the population. The effectiveness of interventions is historically evaluated through examination of group differences in outcome measures. Often the proportions of individuals meeting thresholds for PA outcomes related to intervention implementation are not considered. Our aim was to summarise the effectiveness of structured interventions through reported group differences in outcomes, adoption and maintenance rates, and adherence and retention rates, providing information on intervention feasibility. Methods: Database screening resulted in the inclusion of 12 interventions. Results: There was a tendency for structured programmes to result in a significantly greater increase in PA levels than the control conditions in the short-term, with more varying results in the long-term. Only 3 studies published adoption and maintenance rates. On average 67±16% of participants were reported as adopting PA, with only 29±13% maintaining this effect. A mean retention rate of 75±13% was observed, and 61±21% of intervention sessions were attended as described through adherence rates. Conclusion: Structured interventions were classified as overall effective in short-term on the basis of group differences in PA levels; however, adoption and maintenance rates were rarely reported.

Download Full-text

Addiction Therapeutic communities: residents’ retention, early dropout, and their correlates over fourteen years

10.21203/rs.3.rs-120410/v1 ◽

2020 ◽

Author(s):

Abdulaziz T Alshomrani

Keyword(s):

Program Effectiveness ◽

Demographic Variable ◽

Retention Rate ◽

Critical Time ◽

Drop Out ◽

Retention Rates ◽

Therapeutic Communities ◽

Secondary School Education ◽

Early Dropout

Abstract Background Long-term retention is a reliably well-studied factor associated with enhanced outcomes in addiction therapeutic communities (ATCs). Staying no less than three months is considered to be a critical time for program effectiveness. I plan to estimate retention rates of Saudi AATCs for three months, completion of therapy (stay at least six months), and early abandonment and investigate its correlations in this study. Methods A cohort retrospective study where data of all residents admitted to all Saudi ATCs since their establishment in 2000 through September 2014 were collected from their AATCs files. At the time of the study, there were five AATCs, two of them in Dammam, one in Riyadh, one in Jeddah, and the fifth one was in Taif. Date of admission, date of discharge, socio-demographic variable, and type of drug used of all of the five ACS were reported. Retention rate at 3 and 6 months and dropout in the first week were calculated. Results out of the 2050 files, 2003 of data was suitable for analysis. All of the residents were male adults. More than two-thirds of patients were younger than 40 years of age and most of them were singles (64%), unemployed (68%), and had intermediate or secondary school education (73%). Forty-six percent of patients reported Opioids use, 36% hash, 34% amphetamine, and 19% reported alcohol abuse. The retention rate for three months and six months was 45% and 28% respectively, and 8.3% dropped outs in the first week. The median duration of stay was 77 days. Residences in TC 1, TC 2, and TC 4 were less likely to stay for more than three months. Unemployment, and being students was associated with completion of treatment (stay > 6 months), while admission to TC 1 and TC-2 was associated with drop out prior completing the treatment program. Conclusion Three-month retention rates of 45% in Saudi addiction ATCs is reasonable and consistent with reported rates worldwide. In addition, treatment completion rate and drop out within the first week are at least comparable to the average rates recorded elsewhere. These rates can be considered as indicators for successful Saudi ATCs programs. However, there have been substantial variation between the different Saudi AATCs which may require further exploration to determine the factors related to these disparities.

Download Full-text